Exciting new developments in targeted therapies, using oncoprotein inhibitors such as asciminib and vemurafenib, gene therapies such as nadofaragene firadenovec and talimogene laherparepvec against bladder cancer and melanoma, respectively, as well as immunotherapies like chimeric antigen receptor‐engineered T and natural killer (CAR‐T/NK) cells, bispecific antibodies (Ab) targeting receptors expressed on cancer cells like CD20 or CD3 (odronextamab), and CTLA‐4 or PD‐1 immune checkpoint inhibitors (ipilimumab, nivolumab) have shown impressive preclinical and clinical results.5, 6, 7. This evidence concerns the gene CTLA4 and melanoma.